These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23565287)

  • 21. Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation.
    Zhang L; Lee NJ; Nguyen AD; Enriquez RF; Riepler SJ; Stehrer B; Yulyaningsih E; Lin S; Shi YC; Baldock PA; Herzog H; Sainsbury A
    Diabetes Obes Metab; 2010 Jul; 12(7):591-603. PubMed ID: 20590734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism.
    Cota D; Sandoval DA; Olivieri M; Prodi E; D'Alessio DA; Woods SC; Seeley RJ; Obici S
    Obesity (Silver Spring); 2009 Aug; 17(8):1641-5. PubMed ID: 19325539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior.
    Duarte C; Alonso R; Bichet N; Cohen C; Soubrié P; Thiébot MH
    Neuropsychopharmacology; 2004 May; 29(5):911-20. PubMed ID: 14694354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats.
    Horswill JG; Bali U; Shaaban S; Keily JF; Jeevaratnam P; Babbs AJ; Reynet C; Wong Kai In P
    Br J Pharmacol; 2007 Nov; 152(5):805-14. PubMed ID: 17592509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endocannabinoid signal in the gut controls dietary fat intake.
    DiPatrizio NV; Astarita G; Schwartz G; Li X; Piomelli D
    Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12904-8. PubMed ID: 21730161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control.
    Son MH; Kim HD; Chae YN; Kim MK; Shin CY; Ahn GJ; Choi SH; Yang EK; Park KJ; Chae HW; Moon HS; Kim SH; Shin YG; Yoon SH
    Int J Obes (Lond); 2010 Mar; 34(3):547-56. PubMed ID: 20029379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increase in hypothalamic AMPK phosphorylation induced by prolonged exposure to LPS involves ghrelin and CB1R signaling.
    Rivas PMS; Vechiato FMV; Borges BC; Rorato R; Antunes-Rodrigues J; Elias LLK
    Horm Behav; 2017 Jul; 93():166-174. PubMed ID: 28576646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Additive effects of cannabinoid CB1 receptors blockade and cholecystokinin on feeding inhibition.
    Orio L; Crespo I; López-Moreno JA; Reyes-Cabello C; Rodríguez de Fonseca F; Gómez de Heras R
    Pharmacol Biochem Behav; 2011 Apr; 98(2):220-6. PubMed ID: 21163296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of milk ingestion and growth after administration of a neutral cannabinoid CB1 receptor antagonist on the first postnatal day in the mouse.
    Fride E; Braun H; Matan H; Steinberg S; Reggio PH; Seltzman HH
    Pediatr Res; 2007 Nov; 62(5):533-6. PubMed ID: 17805201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.
    Jacobson LH; Commerford SR; Gerber SP; Chen YA; Dardik B; Chaperon F; Schwartzkopf C; Nguyen-Tran V; Hollenbeck T; McNamara P; He X; Liu H; Seidel HM; Jaton AL; Gromada J; Teixeira S
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Dec; 384(6):565-81. PubMed ID: 21947251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21.
    Pavon FJ; Bilbao A; Hernández-Folgado L; Cippitelli A; Jagerovic N; Abellán G; Rodríguez-Franco MA; Serrano A; Macias M; Gómez R; Navarro M; Goya P; Rodríguez de Fonseca F
    Neuropharmacology; 2006 Aug; 51(2):358-66. PubMed ID: 16750544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
    Després JP
    Crit Pathw Cardiol; 2007 Jun; 6(2):46-50. PubMed ID: 17667864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake.
    Thornton-Jones ZD; Kennett GA; Benwell KR; Revell DF; Misra A; Sellwood DM; Vickers SP; Clifton PG
    Pharmacol Biochem Behav; 2006 Jun; 84(2):353-9. PubMed ID: 16814374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of a shortened model of diet alternation in female rats: effects of the CB1 receptor antagonist rimonabant on food intake and anxiety-like behavior.
    Blasio A; Rice KC; Sabino V; Cottone P
    Behav Pharmacol; 2014 Oct; 25(7):609-17. PubMed ID: 25011007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibiting parabrachial fatty acid amide hydrolase activity selectively increases the intake of palatable food via cannabinoid CB1 receptors.
    Dipatrizio NV; Simansky KJ
    Am J Physiol Regul Integr Comp Physiol; 2008 Nov; 295(5):R1409-14. PubMed ID: 18768763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CB1 receptor blockade counters age-induced insulin resistance and metabolic dysfunction.
    Lipina C; Vaanholt LM; Davidova A; Mitchell SE; Storey-Gordon E; Hambly C; Irving AJ; Speakman JR; Hundal HS
    Aging Cell; 2016 Apr; 15(2):325-35. PubMed ID: 26757949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice.
    Gamble-George JC; Conger JR; Hartley ND; Gupta P; Sumislawski JJ; Patel S
    Psychopharmacology (Berl); 2013 Aug; 228(3):401-9. PubMed ID: 23483200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats.
    Rubio M; Fernández-Ruiz J; de Miguel R; Maestro B; Michael Walker J; Ramos JA
    Neuropharmacology; 2008 May; 54(6):976-88. PubMed ID: 18371990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats.
    Kunz I; Meier MK; Bourson A; Fisseha M; Schilling W
    Int J Obes (Lond); 2008 May; 32(5):863-70. PubMed ID: 18253160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oleamide administered into the nucleus accumbens shell regulates feeding behaviour via CB1 and 5-HT2C receptors.
    Soria-Gómez E; Márquez-Diosdado MI; Montes-Rodríguez CJ; Estrada-González V; Prospéro-García O
    Int J Neuropsychopharmacol; 2010 Oct; 13(9):1247-54. PubMed ID: 20663269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.